Expression of Kinase-defective Mutants of c-Src in Human Metastatic Colon Cancer Cells Decreases Bcl-xL and Increases Oxaliplatin- and Fas-induced Apoptosis*
暂无分享,去创建一个
Paul Workman | Christopher Cawthorne | Caroline Dive | P. Workman | M. Tilby | C. Dive | V. Brunton | M. Frame | G. Griffiths | C. Cawthorne | C. Ottley | D. Pearson | Gareth J Griffiths | Mei Yee Koh | Valerie G Brunton | Natalie A Reeves | Martin Greaves | Michael J Tilby | D Graham Pearson | Christopher J Ottley | Margaret C Frame | M. Koh | M. Greaves
[1] J. Houghton,et al. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] D. Fabbro,et al. Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. , 2004, Bone.
[3] Y. Shiratori,et al. Reduced C‐terminal Src kinase activity is correlated inversely with pp60c‐src activity in colorectal carcinoma , 2001, Cancer.
[4] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[5] G. Evan,et al. Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.
[6] Hua Yu,et al. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential , 1997, Oncogene.
[7] C. Cartwright. Intestinal cell growth control: role of Src tyrosine kinases. , 1998, Gastroenterology.
[8] Y. Tan,et al. Activation and association of Stat3 with Src in v-Src-transformed cell lines , 1996, Molecular and cellular biology.
[9] Y. Hamada,et al. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95‐mediated apoptosis by down‐regulating FLIP‐L expression , 2000, International journal of cancer.
[10] I. Fidler,et al. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. , 1988, Cancer research.
[11] O. Witte,et al. Regulation of Btk by Src family tyrosine kinases , 1996, Molecular and cellular biology.
[12] Apoptosis and cancer chemotherapy. , 2001, Trends in cell biology.
[13] Martin Gs. The hunting of the Src. , 2001 .
[14] R. Danesi,et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] K. Isselbacher,et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[16] C. Dive,et al. Mitochondrial membrane permeabilisation by Bax/Bak. , 2003, Biochemical and biophysical research communications.
[17] D. Stacey,et al. Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide , 1997, Oncogene.
[18] K. Kohno,et al. v‐src induces cisplatin resistance by increasing the repair of cisplatin–DNA interstrand cross‐links in human gallbladder adenocarcinoma cells , 1999, International journal of cancer.
[19] Y. Hakak,et al. Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt , 2000, Oncogene.
[20] E. Avizienyte,et al. Elevated c-Src is linked to altered cell–matrix adhesion rather than proliferation in KM12C human colorectal cancer cells , 2002, British Journal of Cancer.
[21] G. Martin,et al. v-Src Generates a p53-Independent Apoptotic Signal , 2000, Molecular and Cellular Biology.
[22] J. Bjorge,et al. Selected glimpses into the activation and function of Src kinase , 2000, Oncogene.
[23] E. Solary,et al. Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs* , 1999, The Journal of Biological Chemistry.
[24] C. Belka,et al. The tyrosine kinase Lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation , 1999, Oncogene.
[25] J. Darnell,et al. Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.
[26] J. Turkson,et al. Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.
[27] D. Scudiero,et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.
[28] S. Ashley,et al. Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells , 2004, Clinical Cancer Research.
[29] Paul Workman,et al. Translating basic cancer research into new cancer therapeutics. , 2002, Trends in molecular medicine.
[30] J. Filmus,et al. Transforming Growth Factor-α Prevents Detachment-induced Inhibition of c-Src Kinase Activity, Bcl-XLDown-regulation, and Apoptosis of Intestinal Epithelial Cells* , 2001, The Journal of Biological Chemistry.
[31] E. Solary,et al. STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. , 1999, Biochemical and biophysical research communications.
[32] C. Belka,et al. The tyrosine kinase Lck is involved in regulation of mitochondrial apoptosis pathways , 2003, Oncogene.
[33] E. Avizienyte,et al. Src SH3/2 domain-mediated peripheral accumulation of Src and phospho-myosin is linked to deregulation of E-cadherin and the epithelial-mesenchymal transition. , 2004, Molecular biology of the cell.
[34] R. Labianca,et al. Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] Timothy J. Yeatman,et al. Activating SRC mutation in a subset of advanced human colon cancers , 1999, Nature Genetics.
[36] Giulio Superti-Furga,et al. Dynamic Coupling between the SH2 and SH3 Domains of c-Src and Hck Underlies Their Inactivation by C-Terminal Tyrosine Phosphorylation , 2001, Cell.
[37] J. Hanke,et al. Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor , 1996, The Journal of Biological Chemistry.
[38] J. Kinet,et al. Activation of BTK by a Phosphorylation Mechanism Initiated by SRC Family Kinases , 1996, Science.
[39] V. Boudný,et al. Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2 , 2002, British Journal of Cancer.
[40] J. Hickman,et al. Drug-target interactions: only the first step in the commitment to a programmed cell death? , 1991, British Journal of Cancer.
[41] N. Carragher,et al. v-SRC'S hold over actin and cell adhesions , 2002, Nature Reviews Molecular Cell Biology.
[42] Fatih M. Uckun,et al. Bruton’s Tyrosine Kinase as an Inhibitor of the Fas/CD95 Death-inducing Signaling Complex* , 1999, The Journal of Biological Chemistry.
[43] M. Frame,et al. Src in cancer: deregulation and consequences for cell behaviour. , 2002, Biochimica et biophysica acta.
[44] R. Jove,et al. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors , 1999, Oncogene.